These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 499318)

  • 1. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eichelbaum M; Spannbrucker N; Steincke B; Dengler HJ
    Eur J Clin Pharmacol; 1979 Sep; 16(3):183-7. PubMed ID: 499318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the defective metabolism of sparteine on its pharmacokinetics.
    Eichelbaum M; Spannbrucker N; Dengler HJ
    Eur J Clin Pharmacol; 1979 Sep; 16(3):189-94. PubMed ID: 499319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparteine metabolism in Canadian Caucasians.
    Vinks A; Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1982 Jan; 31(1):23-9. PubMed ID: 7053300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple borohydride/GC method for measuring sparteine metabolites in man.
    Inaba T; Vinks A; Otton SV
    Br J Clin Pharmacol; 1986 May; 21(5):473-80. PubMed ID: 3718806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
    Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
    Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.
    Eichelbaum M; Woolhouse NM
    Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
    Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
    Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparteine metabolism in a Nigerian population.
    Ritchie JC; Mitchell SC; Smith RL
    Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparteine oxidation is practically abolished in quinidine-treated patients.
    Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
    Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
    Nielsen MD; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.